A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma.
Not Applicable
Completed
- Conditions
- advanced melanoma
- Registration Number
- JPRN-UMIN000020222
- Lead Sponsor
- Tohoku University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
hypersensitibity against nivolumab
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse event Maximum tolerated dose (MTD) At 6 weeks, we assess the primary outcomes and will observe during 6 months.
- Secondary Outcome Measures
Name Time Method